home / stock / xncr / xncr news

XNCR News and Press, Xencor Inc. From 07/08/20

Stock Information
Company Name: Xencor Inc.
Stock Symbol: XNCR
Market: NASDAQ
Website: xencor.com
Menu
XNCR XNCR Quote XNCR Short XNCR News XNCR Articles XNCR Message Board
Get XNCR Alerts

News, Short Squeeze, Breakout and More Instantly...
XNCR - Atreca teams up with Xencor to develop T cell engaging antibodies

Atreca (NASDAQ: BCEL ) is  up 6%  premarket after entering into a collaboration and license agreement with Xencor (NASDAQ: XNCR ) to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncology. More news on: Atreca, Inc.,...
XNCR - Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human ...

XNCR - Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics ge...

XNCR - Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new preclinical data from three XmAb ® 2+1 bispecific antibody programs and its IL...
XNCR - Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical data on three XmAb ® 2+1 bispecific antibody programs and an IL-12-Fc ...

XNCR - Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

-- XmAb20717 generally well-tolerated and a confirmed complete response (CR) observed at highest dose level tested -- -- Robust, dose-dependent immune activation consistent with inhibition of both PD-1 and CTLA-4 checkpoints -- -- Further dose-escalation and expansion cohorts cont...

XNCR - Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a fireside chat at th...
XNCR - Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2020 Results - Earnings Call Transcript

Xencor, Inc. (XNCR) Q1 2020 Earnings Conference Call May 07, 2020, 04:30 PM ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications and IR Bassil Dahiyat - President and CEO John Kuch - SVP and CFO Allen Yeng - SVP and Chief Medical Officer...

XNCR - Xencor Inc (XNCR) Q1 2020 Earnings Call Transcript

Image source: The Motley Fool. Xencor Inc   (NASDAQ: XNCR) Q1 2020 Earnings Call May 8, 2020 , 10:30 p.m. ET Operator Continue reading

XNCR - Xencor EPS beats by $0.25, beats on revenue

Xencor (NASDAQ: XNCR ): Q1 GAAP EPS of -$0.14 beats by $0.25 . Revenue of $32.4M (-71.1% Y/Y) beats by $17.74M . Press Release More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news,

Previous 10 Next 10